The use of psychotropic medication during pregnancy: How about the newborn?

Neuropsychiatric Disease and Treatment

Volumn 9, Issue , 2013, Pages 1257-1266

  Kieviet, Noera ^a   Dolman, Koert M ^a   Honig, Adriaan ^a  

^a ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

Antidepressants; Neonatal abstinence; Psychiatric disorders; SSRI; Withdrawal

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOMIPRAMINE; CLONAZEPAM; DIAZEPAM; FLUOXETINE; LITHIUM; MIRTAZAPINE; NEUROLEPTIC AGENT; NITRAZEPAM; OPIATE DERIVATIVE; OXAZEPAM; PAROXETINE; PHENOBARBITAL; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TEMAZEPAM; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE;

ADVERSE DRUG REACTION; ANTICHOLINERGIC EFFECT; ANXIETY; AUTONOMIC DYSFUNCTION; BREAST FEEDING; CONVULSION; DIAGNOSTIC TEST; DIET THERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL DISEASE; HEREDITY; HUMAN; HYPERBILIRUBINEMIA; HYPOGLYCEMIA; INFECTION; INTOXICATION; MENTAL DISEASE; MONOTHERAPY; NEUROLOGIC DISEASE; NEWBORN; NEWBORN DISEASE; POOR NEONATAL ADAPTATION; PRACTICE GUIDELINE; PREGNANCY; PREMATURITY; PRENATAL DRUG EXPOSURE; PUERPERAL DEPRESSION; RESPIRATORY TRACT DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SYMPTOM; TOXICITY TESTING; TREATMENT DURATION; TREATMENT PLANNING; URINALYSIS;

EID: 84883444642     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S36394     Document Type: Review

References (104)

1. Marcus SM, Flynn HA, Blow FC, Barry KL. Depressive symptoms among pregnant women screened in obstetrics settings. J Womens Health (Larchmt). 2003;12(4):373-380. doi:10.1089/154099903765448880
2. Andersson L, Sundstromporomaa L, Bixo M, Wuff M, Bondestam K, Astrom M. Point prevalence of psychiatric disorders during the second trimester of pregnancy: A population-based study. American Journal of Obstetrics and Gynecology. 2003;189(1):148-154. doi:10.1067/mob.2003.336
3. Goedhart G, Snijders AC, Hesselink AE, van Poppel MN, Bonsel GJ, Vrijkotte TGM. Maternal Depressive Symptoms in Relation to Perinatal Mortality and Morbidity: Results From a Large Multiethnic Cohort Study. Psychosomatic Medicine. 2010;72(8):769-776. doi:10.1097/PSY.0b013e3181ee4a62
4. Lee H-C, Lin H-C. Maternal bipolar disorder increased low birthweight and preterm births: A nationwide population-based study. Journal of Affective Disorders. 2010;121(1-2):100-105. doi:10.1016/j. jad.2009.05.019
5. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry. 2006;63(8):898-906. doi:10.1001/archpsyc.63.8.898
6. Field T, Diego M, Hernandez-Reif M. Prenatal depression effects and interventions: A review. Infant Behavior and Development. 2010;33(4):409-418. doi:10.1016/j. infbeh.2010.04.005
7. Zuckerman B, Bauchner H, Parker S, Cabral H. Maternal depressive symptoms during pregnancy, and newborn irritability. J Dev Behav Pediatr. 1990;11(4):190-194.
8. Lundy B. Prenatal depression effects on neonates. Infant Behavior and Development. 1999;22(1):119-129. doi:10.1016/S0163-S6383(99) 80009-5.
9. Hay DF, Pawlby S, Waters CS, Sharp D. Antepartum and postpartum exposure to maternal depression: different effects on different adolescent outcomes. Journal of Child Psychology and Psychiatry. 2008;49(10):1079-1088. doi:10.1111/j.1469-7610.2008.01959. x
10. Wan MW, Salmon MP, Riordan DM, Appleby L, Webb R, Abel KM. What predicts poor mother-infant interaction in schizophrenia? Psychol. Med. 2006;37(04):537. doi:10.1017/S0033291706009172
11. Murray L, Fiori-Cowley A, Hooper R, Cooper P. The impact of postnatal depression and associated adversity on early mother-infant interactions and later infant outcome. Child Dev. 1996;67(5):2512-2526.
12. Bellantuono C, Bozzi F, Orsolini L, Catena-Dell'Osso M. The safety of escitalopram during pregnancy and breastfeeding: a comprehensive review. Hum Psychopharmacol. 2012;27(6):534-539. doi:10.1002/hup.2265
13. Yonkers KA, Wisner KL, Stewart DE, etal. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologistshhh. General Hospital Psychiatry. 2009;31(5):403-413. doi:10.1016/j. genhosppsych.2009.04.003.
14. NICE. Antenatal and postnatal mental health. National Institute for Clinical Excellence. 2007:1-51.
15. Bellantuono C, Migliarese G, Gentile S. Serotonin reuptake inhibitors in pregnancy and the risk of major malformations: a systematic review. Hum Psychopharmacol. 2007;22(3):121-128. doi:10.1002/hup.836.
16. Haddad P. Antidepressant discontinuation syndromes: clinical relevance, prevention and management. Drug Safety. 2001;24(3):183-197.
17. Galbally M, Lewis AJ, Lum J, Buist A. Serotonin discontinuation syndrome following in utero exposure to antidepressant medication: prospective controlled study. Aust N Z J Psychiatry. 2009;43(9):846-854. doi:10.1080/00048670903107583
18. Newport DJ, Viguera AC, Beach AJ, Ritchie JC, Cohen LS, Stowe ZN. Lithium placental passage and obstetrical outcome: implications for clinical management during late pregnancy. Am J Psychiatry. 2005;162(11):2162-2170. doi:10.1176/appi. ajp.162.11.2162
19. Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin M, Mintz J. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry. 1996;153(5):592-606.
20. Rampono J, Simmer K, Ilett KF, etal. Placental Transfer of SSRI and SNRI Antidepressants and Effects on the Neonate. Pharmacopsychiatry. 2009;42(03):95-100. doi:10.1055/s-0028-1103296
21. Boucher N, Bairam A, Beaulac-Baillargeon L. A new look at the neonate's clinical presentation after in utero exposure to antidepressants in late pregnancy. Journal of Clinical Psychopharmacology. 2008;28(3):334-339. doi:10.1097/JCP.0b013e318173aa2e
22. Koren G. Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates? Canadian Medical Association Journal. 2005;172(11):1457-1459. doi:10.1503/cmaj.1041100
23. Klinger G, Merlob P. Selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. Isr J Psychiatry Relat Sci. 2008;45(2): 107-113.
24. Sie SD, Wennink JMB, van Driel JJ, etal. Maternal use of SSRIs, SNRIs and NaSSAs: practical recommendations during pregnancy and lactation. Archives of Disease in Childhood-Fetal and Neonatal Edition. 2012;97(6):F472-F476. doi:10.1136/archdischild-2011-214239.
25. Anbu AT, Theodore A. Fluoxetine withdrawal syndrome in the newborn. Indian Pediatr. 2006;43(1):66-69.
26. Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med. 2006;160(2):173-176. doi:10.1001/archpedi.160.2.173
27. Oberlander TF, Misri S, Fitzgerald CE, Kostaras X, Rurak D, Riggs W. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry. 2004;65(2):230-237.
28. Laine K, Heikkinen T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry. 2003;60(7):720-726. doi:10.1001/archpsyc.60.7.720
29. Isbister GK, Dawson A, Whyte IM, Prior FH, Clancy C, Smith AJ. Neonatal paroxetine withdrawal syndrome or actually serotonin syndrome? Archives of Disease in Childhood-Fetal and Neonatal Edition. 2001;85(2):F147-F148.
30. Knoppert DC, Nimkar R, Principi T, Yuen D. Paroxetine toxicity in a newborn after in utero exposure: clinical symptoms correlate with serum levels. In: 2006;28:5-7.
31. Stiskal JA. Defective alleles may not have contributed to adverse effects. Ther Drug Monit. 2006;28(1):142-author reply 143.
32. Hudak ML, Tan RC. Newborn COFA, American Academy of Pediatrics, Newcomb C, drugs CO. Neonatal drug withdrawal. PEDIATRICS. 2012;129(2):e540-e560. doi:10.1542/peds.2011-3212
33. Bellissima V, Ververs TFF, Visser GHA, Gazzolo D. Selective serotonin reuptake inhibitors in pregnancy. Curr Med Chem. 2012;19(27): 4554-4561.
34. Sanz EJ, De-las-Cuevas C, Kiuru A, Bate A, Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet. 2005;365(9458):482-487. doi:10.1016/S0140-6736(05)17865-9
35. Gentile S. On categorizing gestational, birth, and neonatal complications following late pregnancy exposure to antidepressants: the prenatal antidepressant exposure syndrome. CNS Spectr. 2010;15(3):167-185.
36. Byatt N, Deligiannidis KM, Freeman MP. Antidepressant use in pregnancy: a critical review focused on risks and controversies. Acta Psychiatrica Scandinavica. 2013;127(2):94-114. doi:10.1111/acps.12042
37. Jansson LM, Velez M. Neonatal abstinence syndrome. Curr Opin Pediatr. 2012;24(2):252-258. doi:10.1097/MOP.0b013e32834fdc3a
38. Field T. Prenatal Depression and Selective Serotonin Reuptake Inhibitors. Int J Neurosci. 2010;120(3):163-167. doi:10.3109/00207450802338697
39. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. The British Journal of Psychiatry. 2008;192(5):338-343. doi:10.1192/bjp. bp.107.037101
40. Zeskind PS, Stephens LE. Maternal Selective Serotonin Reuptake Inhibitor Use During Pregnancy and Newborn Neurobehavior. PEDIATRICS. 2004;113(2):368-375. doi:10.1542/peds.113.2.368
41. Horst Ter PGJ, van der Linde S, Smit JP, etal. Clomipramine concentration and withdrawal symptoms in ten neonates. Br J Clin Pharmacol. 2011:1-8. doi:10.1111/j.1365-2125.2011.04072. x
42. Ferreira E, Carceller AM, Agogue C, etal. Effects of Selective Serotonin Reuptake Inhibitors and Venlafaxine During Pregnancy in Term and Preterm Neonates. PEDIATRICS. 2007;119(1):52-59. doi:10.1542/peds.2006-2133
43. Uzun S, Kozumplik O, Jakovljević M, Sedić B. Side effects of treatment with benzodiazepines. Psychiatr Danub. 2010;22(1):90-93.
44. Galbally M, Snellen M, Walker S, Permezel M. Management of antipsychotic and mood stabilizer medication in pregnancy: recommendations for antenatal care. Aust N Z J Psychiatry. 2010;44(2):99-108. doi:10.3109/00048670903487217
45. Scheffers TPH, Enk JG. Gevolgen ssri-gebruik zwangeren bij de pasgeborene in de eerste 48 uur post partum. [Neonatal effects of SSRI-use during pregnancy during the first 48 hours after birth]. KIND. 2007;75(4):159-164. doi:10.1007/BF03061685
46. Udechuku A, Nguyen T, Hill R, Szego K. Antidepressants in pregnancy: a systematic review. Aust N Z J Psychiatry. 2010;44(11):978-996. doi:10.3109/00048674.2010.507543
47. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335(14):1010-1015. doi:10.1056/NEJM199610033351402
48. Alwan S, Friedman JM. Safety of selective serotonin reuptake inhibitors in pregnancy. CNS Drugs. 2009;23(6):493-509. doi:10.2165/00023210-200923060-00004
49. Källén B, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidem Drug Safe. 2008;17(8):801-806. doi:10.1002/pds.1570
50. Coppola D, Russo LJ, Kwarta RF, Varughese R, Schmider J. Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes. Drug Saf. 2007;30(3):247-264.
51. Grzeskowiak LE, Gilbert AL, Morrison JL. Investigating outcomes following the use of selective serotonin reuptake inhibitors for treating depression in pregnancy: a focus on methodological issues. Drug Saf. 2011;34(11):1027-1048. doi:10.2165/11593130-000000000-00000
52. Malm H. Prenatal exposure to selective serotonin reuptake inhibitors and infant outcome. Ther Drug Monit. 2012;34(6):607-614. doi:10.1097/FTD.0b013e31826d07ea
53. Kendall-Tackett K, Hale TW. The use of antidepressants in pregnant and breastfeeding women: a review of recent studies. J Hum Lact. 2010;26(2):187-195. doi:10.1177/0890334409342071
54. McElhatton PR. The effects of benzodiazepine use during pregnancy and lactation. Reprod Toxicol. 1994;8(6):461-475.
55. Koren G, Finkelstein Y, Matsui D, Berkovich M. Diagnosis and management of poor neonatal adaptation syndrome in newborns exposed in utero to selective seretonin/norepinephrine reuptake inhibitors. J Obstet Gynaecol Can. 2009;31(4):348-350.
56. Lattimore KA, Donn SM, Kaciroti N, Kemper AR, Neal CR, Vazquez DM. Selective Serotonin Reuptake Inhibitor (SSRI) Use during Pregnancy and Effects on the Fetus and Newborn: A Meta-Analysis. J Perinatol. 2005;25(9):595-604. doi:10.1038/sj. jp.7211352
57. Oyebode F, Rastogi A, Berrisford G, Coccia F. Psychotropics in pregnancy: safety and other considerations. Pharmacol Ther. 2012;135(1):71-77. doi:10.1016/j. pharmthera.2012.03.008
58. Krüger S. Psychopharmacological Treatment of Mood and Anxiety Disorders During Pregnancy. In: Handbook of Experimental Pharmacology. Handbook of Experimental Pharmacology. Berlin, Heidelberg: Springer Berlin Heidelberg; 2012;214:279-305. doi:10.1007/978-3-642-30726-3-14.
59. Gentile S. Drug treatment for mood disorders in pregnancy. Curr Opin Psychiatry. 2011;24(1):34-40. doi:10.1097/YCO.0b013e3283413451
60. Hauser LA. Pregnancy and psychiatric drugs. Hosp Community Psychiatry. 1985;36(8):817-818.
61. Miller LJ. Psychopharmacology during pregnancy. Prim Care Update Ob/Gyn. 1996;3(3):79-85.
62. Sitland-Marken PA, Rickman LA, Wells BG, Mabie WC. Pharmacologic management of acute mania in pregnancy. Journal of Clinical Psychopharmacology. 1989;9(2):78-87.
63. Levy M, Spino M. Neonatal withdrawal syndrome: associated drugs and pharmacologic management. Pharmacotherapy. 1993;13(3): 202-211.
64. Patil AS, Kuller JA, Rhee EHJ. Antidepressants in pregnancy: a review of commonly prescribed medications. Obstet Gynecol Surv. 2011;66(12):777-787. doi:10.1097/OGX.0b013e31823e0cbf
65. Bakker MK, Kölling P, van den Berg PB, de Walle HEK, de Jong-van den Berg LTW. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol. 2008;65(4):600-606. doi:10.1111/j.1365-2125.2007.03048. x
66. Reefhuis J, Friedman J. Selective serotinin-reuptake inhibitors and persistent pulmonary hypertension of the newborn. N England Journal of Medicine. 2006;354:2188-2189.
67. Ververs T, van Dijk L, Yousofi S, Schobben F, Visser GH. Depression during pregnancy: views on antidepressant use and information sources of general practitioners and pharmacists. BMC Health Serv Res. 2009;9(1):119. doi:10.1186/1472-6963-9-119
68. Seligman NS, Almario CV, Hayes EJ, Dysart KC, Berghella V, Baxter JK. Relationship between maternal methadone dose at delivery and neonatal abstinence syndrome. J Pediatr. 2010;157(3):428-433. e1. doi:10.1016/j. jpeds.2010.03.033
69. Moses-Kolko EL, Bogen D, Perel J, etal. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005;293(19):2372-2383. doi:10.1001/jama.293.19.2372
70. Misri S, Oberlander TF, Fairbrother N, etal. Relation between prenatal maternal mood and anxiety and neonatal health. Can J Psychiatry. 2004;49(10):684-689.
71. Trenque T, Piednoir D, Frances C, Millart H, Germain ML. Reports of withdrawal syndrome with the use of SSRIs: a case/non-case study in the French Pharmacovigilance database. Pharmacoepidem Drug Safe. 2002;11(4):281-283. doi:10.1002/pds.704
72. Källén B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med. 2004;158(4):312-316. doi:10.1001/archpedi.158.4.312
73. van Driel JJ, Wennink JHMB, Heres MHB, Honig A. Intrauterine exposure to SSRIs: no reason for routine hypoglycaemia screening. Ned Tijdschr Geneeskd. 2010;154(8):A339.
74. 't Jong GW, Einarson T, Koren G, Einarson A. Antidepressant use in pregnancy and persistent pulmonary hypertension of the newborn (PPHN): a systematic review. Reprod Toxicol. 2012;34(3):293-297. doi:10.1016/j. reprotox.2012.04.015
75. Food and Drug Administration advise on drug safety. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm283375.htm. Accessed May 24, 2013.
76. Horst Ter PGJ, Jansman FGA, van Lingen RA, Smit J-P, de Jong-van den Berg LTW, Brouwers JRBJ. Pharmacological aspects of neonatal antidepressant withdrawal. Obstet Gynecol Surv. 2008;63(4):267-279. doi:10.1097/OGX.0b013e3181676be8
77. Stewart DE. Clinical practice. Depression during pregnancy. N Engl J Med. 2011;365(17):1605-1611. doi:10.1056/NEJMcp1102730
78. Gentile S. The safety of newer antidepressants in pregnancy and breastfeeding. Drug Saf. 2005;28(2):137-152.
79. Boucher N, Koren G, Beaulac-Baillargeon L. Maternal use of venlafaxine near term: correlation between neonatal effects and plasma concentrations. Ther Drug Monit. 2009;31(3):404-409. doi:10.1097/FTD.0b013e3181a58fb4
80. Nielsen RE, Damkier P. Pharmacological treatment of unipolar depression during pregnancy and breast-feeding-a clinical overview. Nord J Psychiatry. 2012;66(3):159-166. doi:10.3109/08039488.2011.650198
81. Newport DJ, Calamaras MR, DeVane CL, etal. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry. 2007;164(8):1214-1220. doi:10.1176/appi. ajp.2007.06111886
82. Galbally M, Snellen M, Lewis AJ. A review of the use of psychotropic medication in pregnancy. Curr Opin Obstet Gynecol. 2011;23(6):408-414. doi:10.1097/GCO.0b013e32834b92f3
83. Gentile S. Lithium in pregnancy: the need to treat, the duty to ensure safety. Expert Opin Drug Saf. 2012;11(3):425-437. doi:10.1517/14740338.2012.670419
84. Galbally M, Roberts M, Buist A. Perinatal Psychotropic Review Group. Mood stabilizers in pregnancy: a systematic review. Aust N Z J Psychiatry. 2010;44(11):967-977. doi:10.3109/00048674.2010.506637
85. Iqbal MM, Sohhan T, Mahmud SZ. The effects of lithium, valproic acid, and carbamazepine during pregnancy and lactation. J Toxicol Clin Toxicol. 2001;39(4):381-392.
86. Ananth J. Side effects on fetus and infant of psychotropic drug use during pregnancy. Int Pharmacopsychiatry. 1976;11(4):246-260.
87. Kozma C. Neonatal toxicity and transient neurodevelopmental deficits following prenatal exposure to lithium: Another clinical report and a review of the literature. Am J Med Genet. 2005;132A(4):441-444. doi:10.1002/ajmg.a.30501
88. Robinson GE, Stewart DE, Flak E. The rational use of psychotropic drugs in pregnancy and postpartum. Can J Psychiatry. 1986;31(3): 183-190.
89. Kanto J, Erkkola R. Obstetric analgesia: pharmacokinetics and its relation to neonatal behavioral and adaptive functions. Biol Res Pregnancy Perinatol. 1984;5(1):23-35.
90. García-Algar O. Nicotine withdrawal symptoms in newborns. Arch Bronconeumol. 2008;44(10):509-511.
91. Sit D, Perel JM, Wisniewski SR, Helsel JC, Luther JF, Wisner KL. Mother-Infant Antidepressant Concentrations, Maternal Depression, and Perinatal Events. J Clin Psychiatry. 2011;72(07):994-1001. doi:10.4088/JCP.10 m06461
92. Costei AM, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med. 2002;156(11):1129-1132.
93. Whitelaw AG, Cummings AJ, McFadyen IR. Effect of maternal lorazepam on the neonate. Br Med J (Clin Res Ed). 1981;282(6270): 1106-1108.
94. Warburton W, Hertzman C, Oberlander TF. A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. Acta Psychiatrica Scandinavica. 2009;121(6):471-479. doi:10.1111/j.1600-0447.2009.01490. x
95. Abdel-Latif ME. Effects of Breast Milk on the Severity and Outcome of Neonatal Abstinence Syndrome Among Infants of Drug-Dependent Mothers. PEDIATRICS. 2006;117(6):e1163-e1169. doi:10.1542/peds.2005-1561
96. McQueen KA, Murphy-Oikonen J, Gerlach K, Montelpare W. The impact of infant feeding method on neonatal abstinence scores of methadone-exposed infants. Adv Neonatal Care. 2011;11(4):282-290. doi:10.1097/ANC.0b013e318225a30c
97. Koren G, Moretti M, Kapur B. Can venlafaxine in breast milk attenuate the norepinephrine and serotonin reuptake neonatal withdrawal syndrome. J Obstet Gynaecol Can. 2006;28(4):299-302.
98. Oberlander TF, Bonaguro RJ, Misri S, Papsdorf M, Ross CJD, Simpson EM. Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Mol Psychiatry. 2007;13(1):65-73. doi:10.1038/sj. mp.4002007
99. Bot P. Neonatal effects of exposure to selective serotonin reuptake inhibitors during pregnancy. Archives of Disease in Childhood-Fetal and Neonatal Edition. 2006;91(2):F153-F153. doi:10.1136/adc.2004.066431
100. Kieviet N, Dolman K, Wennink H, Heres M, Honig A. Withdrawal in newborns after exposure to psychotropic medications during pregnancy. Ned Tijdschr Geneeskd. 2012;156(16):A4395.
101. Austin M-P. To treat or not to treat: maternal depression, SSRI use in pregnancy and adverse neonatal effects. Psychol Med. 2006;36(12):1663. doi:10.1017/S003329170600835X
102. Finnegan LP, Kron RE, Connaughton JF, Emich JP. Assessment and treatment of abstinence in the infant of the drug-dependent mother. Int J Clin Pharmacol Biopharm. 1975;12(1-2):19-32.
103. Vento M, de Vries LS, Alberola A, etal. Approach to seizures in the neonatal period: a European perspective. Acta Paediatrica. 2010;99(4):497-501. doi:10.1111/j.1651-2227.2009.01659. x
104. Klinger G, Frankenthal D, Merlob P, et al. Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. J Perinatol. 2011. doi:10.1038/jp.2010.211